316

  • Web Address
  • DOI
  • Date of creation in the UzSCI system 12-04-2020
  • Read count 284
  • Date of publication 03-05-2018
  • Main LanguageRus
  • Pages31-34
Tags
Ўзбек

Тадқиқот мақсади нефрэктомиядан сўнг ўтказилган иммуно ва таргет терапияларини даволаш натижаларини таққослаш бўлиб, унинг натижалари буйрак саратонини метастази кузатилган 126 та беморга ўрганилган. Улардан 62 (49.2%) беморда метахрон метастозлар кузатилган бўлиб, радикал нефрэктомиядан сўнг ўртача 11 ойдан кейин пайдо бўлган. Синхрон метастазлар 64 (50,8% ) беморда кузатилган бўлиб, уларнинг барчасига асоратларни олдини олиш мақсадида паллиатив нефрэктомия амалиёти бажарилган.

Амалиётдан сўнг ўтказилган даволашни усулига асосан беморлар 2 гурухга бўлинган. 1 гурух П-82 нефрэктомия + иммунотерапия. 2 гурух П-44 нефрэктомия + таргет терапия (сарафиниб). Ўтказилган даво усулларини бевосита ўрганиш шуни кўрсатдики, даволаш воситаларини қабул қилиш, ножўя таъсирларни рўй бериши ва бевосита клиник самарадорликга эришиш мезонлари бўйича ҳар иккала гурухда ҳам деярли бир хил натижаларга эришилган бўлиб, уларни орасида статистик фарк йўқ (Р<0,05). Лекин 3 йиллик яшаш муддати бўйича статистик исботланган фарқ мавжуд бўлиб, бу яшаш муддати 1 гр 18, 4% 2,3 ва 2 гр 24,3+22% тенг бўлади.(Р>0,05). 5 - йиллик яшаш муддати 0%. Ўтказилган тадқиқот таргет терапияси иммуно терапияга қараганда 3 йиллик яшаш кўрсаткичи бўйича нисбатан афзалликга эга эканлигини кўрсатади.

English

The aim of the study was a comparative assessment of the effectiveness of immunotherapy and targeted therapy after nephrectomy. With this aim, the study was conducted in 126 cancer patients with metastases of different localization. Of these, 62 (49.2%) patients had metachronous metastases on average 11 months after radical nephrectomy, and 64 (50.8%) had synchronous metastases to prevent possible complications was performed palliative nephrectomy

Depending on the methods of treatment, patients were divided into 2 groups. 1 group n=82 nephrectomy + immunotherapy. 2 group n = 44 nephrectomy + targeted therapy. Comparative evaluation of the drug tolerance, severity of side effects and the immediate effectiveness of the compared methods of treatment significant differences between the groups were not found (p< 0.05). The three-year survival rate was 18.4±2.3% and 24.3±2.2% respectively (p > 0.05)/ five-year survival rate was 0%. The results of the study showed that targeted therapy has a significantly better three-year survival than immunotherapy

№ Author name position Name of organisation
1 Jurayev M.D.
2 Jurayev A.T.
№ Name of reference
1 1. Алексеев Б.Я., Калпинский А.С. Новые воз-можности таргетной терапии метастатического рака почки// Онкоурология 2009 №3 стр 8-13. 2. Киркали З., Эрдем Канда A. Современные подходы к лечению почечно-клеточного рака// Онкоурология 2006 №1 стр. 17-24. 3. Матвеев В.Б., Волкова М.И. Рекомендации Европейской Ассоциации урологов по лечению рака почки// Онкоурология 2008 №1 стр. 21-25. 4. Шамсиев А. М. и др. Диагностика и лечение эхинококкоза почек //Новые технологии в детской хирургии. – 2014. – С. 279-283. 5. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108. 6. Tsimafeyeu I., Aksel E. Renal cell carcinoma in the Russian Federation in 2008. J Malignant Tumors 2010;2:3-4. 7. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2. Cancer 1997;80:1198-220. 8. Shamsiyev A. M., Khusinova S. A. The Influence of Environmental Factors on Human Health in Uzbekistan //The Socio-Economic Causes and Consequences of Desertification in Central Asia. – Springer, Dordrecht, 2008. – С. 249-252. 9. Sternberg C., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8. 10. Yang J.C., Hughes M., Kammula U. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.J Immunother 2007;30(8):825-30. 11. Amin A.D.A., Logan T. A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinom in combination with sunitinib. J Clin Oncol 2010;28:4588.
Waiting